If you have been reading about Novel food and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality control for NMN materials typically includes appearance, assay, impurity profile, residual solvents, heavy metals, and microbial limits. A certificate of analysis summarizes specified tests, but the underlying methods and laboratory accreditation matter. Regulatory treatment varies by country; NMN is sold as a dietary supplement in some markets, while other jurisdictions restrict its use in foods or classify it differently. Independent verification can reduce risks of mislabeling or substitution. Questions remain about how product purity, storage history, and formulation affect delivered dose in humans.
Solid NMN is a polar, water-soluble nucleotide that can absorb moisture from air. Its phosphate ester is susceptible to hydrolysis, and degradation is faster in aqueous solution, under strongly acidic or alkaline conditions, and at elevated temperatures. For laboratory and commercial handling, the solid is typically kept desiccated, protected from light, and stored frozen. Repeated freeze-thaw cycles can introduce moisture and accelerate breakdown. Stability data for specific formulations should be generated rather than assumed from the parent compound.
Identity and purity of NMN are commonly assessed by liquid chromatography with ultraviolet detection or mass spectrometry. High-performance liquid chromatography can separate related impurities such as nicotinamide, nicotinamide riboside, and NAD+ depending on the method. Mass spectrometry provides molecular mass confirmation, while nuclear magnetic resonance spectroscopy helps establish structure and anomeric form. Quantitative assays often use calibration curves and, in biological samples, stable isotope-labeled internal standards. Method validation addresses specificity, linearity, accuracy, precision, and limits of detection.
NMN is generally handled as a hygroscopic and light-sensitive solid in laboratory settings. Recommended storage is typically at -20°C or below, often under desiccation and protected from light. Aqueous solutions are less stable than the solid and may degrade through hydrolysis or other pathways, so fresh preparation is common for analytical work. Repeated freeze-thaw cycles can reduce sample integrity. Stability depends on pH, temperature, buffer composition, and the presence of metal ions, so specific shelf-life values should be determined experimentally rather than assumed.
Quality control for NMN samples often includes purity determination by HPLC, identity confirmation by mass spectrometry or NMR, and water content measurement by Karl Fischer titration. Certificates of analysis may report residual solvents, heavy metals, and microbial limits depending on the intended use. Purity values are method-dependent, so a stated percentage should be interpreted alongside the analytical procedure and detection wavelength. Reference standards help ensure that retention times and spectral data are comparable across laboratories. Researchers increasingly request independent verification because supply chains for specialty chemicals can vary in documentation.
Common laboratory methods for NMN include high-performance liquid chromatography with ultraviolet detection, liquid chromatography coupled to mass spectrometry, and nuclear magnetic resonance spectroscopy. Because the nicotinamide ring absorbs ultraviolet light, HPLC-UV at wavelengths near 260 nm can be used for purity assessment. LC-MS and LC-MS/MS provide greater sensitivity and are often applied to biological samples. Identification typically relies on matching retention time, mass-to-charge ratio, and fragmentation pattern to a reference standard.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual description varies by grade |
| Solubility class | Freely soluble in water | Polar nucleotide; less soluble in organic solvents |
| Typical storage temperature | -20°C or below | Protect from moisture and light; desiccated |
| Common analytical method | HPLC-UV or LC-MS | Used for identity and purity; NMR for structure |
| Hygroscopicity | Hygroscopic | Absorbs moisture; keep sealed |
Quantifying NMN requires methods that separate it from structurally similar compounds such as nicotinamide, nicotinamide riboside, and NAD+. Common approaches include high-performance liquid chromatography coupled with ultraviolet detection, liquid chromatography with tandem mass spectrometry, capillary electrophoresis, and nuclear magnetic resonance for identity confirmation. Because NMN is polar and often present at low concentrations in biological samples, sample preparation can involve protein precipitation, solid-phase extraction, or derivatization. Isotope-labeled internal standards help correct for matrix effects and recovery losses. Reported concentrations depend heavily on the matrix, extraction protocol, and analytical platform.
Stability of NMN depends on physical form, temperature, moisture, light, and pH. The solid compound is generally more stable than aqueous solutions, which can degrade over time, especially when warm or exposed to extreme pH. Recommended laboratory storage is typically desiccated at −20 °C or below, protected from light, with containers sealed to limit moisture uptake. In solution, degradation products may include nicotinamide and related ribosides, and the rate varies with buffer composition and concentration. Analytical laboratories often prepare fresh solutions and validate stability for each method.
Solid NMN is generally handled as a moisture-sensitive and light-sensitive material. Suppliers commonly recommend storage at minus 20 degrees Celsius in a sealed, desiccated container, protected from light. Aqueous solutions are less stable than the solid and may degrade faster at elevated temperatures or extreme pH values. Because NMN contains a phosphate ester and a glycosidic bond, hydrolysis and other degradation pathways are plausible under unfavorable conditions. Stability data from independent laboratories remain limited, so handling recommendations often reflect supplier practice rather than published consensus.
Analytical measurement of NMN typically uses high-performance liquid chromatography with ultraviolet detection, often at a wavelength near 260 nanometers. Liquid chromatography coupled with tandem mass spectrometry provides greater sensitivity and specificity, especially for biological samples. Nuclear magnetic resonance spectroscopy can confirm structure and detect certain impurities. Purity values reported by suppliers depend on the analytical method, calibration standards, and whether related compounds such as nicotinamide or NAD+ are included in the calculation. Independent verification is useful because supplement labels may not fully describe the tested material.
Regulatory treatment of NMN differs by country and has changed over time. In the United States, the Food and Drug Administration has stated that NMN is excluded from the definition of a dietary supplement because it was investigated as a drug before being marketed as a supplement; enforcement and legal interpretation continue to evolve. In the European Union, NMN may require authorization as a novel food before sale. In Japan, NMN has been marketed in some food products, while it is not approved as a therapeutic drug in major markets. These categories affect labeling, permitted claims, and quality oversight.
Stability studies indicate that NMN is sensitive to heat, light, and pH extremes. In aqueous solution, hydrolysis can cleave the phosphate linkage or convert NMN to related nicotinamide derivatives, with degradation accelerating at elevated temperatures and alkaline conditions. Solid material is generally more stable when kept dry and cold, and research-grade supplies are often stored at minus twenty degrees Celsius or lower, protected from light and moisture. Repeated freeze-thaw cycles of solutions can promote degradation, so aliquoting is a common laboratory practice. The exact shelf life depends on purity, counterion, packaging, and storage history.
Quality control for NMN focuses on identity, purity, and the absence of harmful contaminants. Certificates of analysis may report high-performance liquid chromatography purity, mass spectrometry identity, residual solvents, heavy metals, and microbial limits, depending on grade and intended use. Because NMN can exist as different isomers, salts, or hydrates, specification sheets should state the exact form being tested. There is no single globally harmonized purity standard for NMN products. Open questions include which degradation products are most relevant under real-world storage and how analytical results from different laboratories can be compared reliably.
Analytical identification of NMN usually combines chromatographic separation with mass spectrometric detection. High-performance liquid chromatography coupled to tandem mass spectrometry is common for quantifying NMN in biological matrices and finished materials. Because NMN and related nucleotides share similar masses and retention behavior, method development must resolve potential interferences such as nicotinamide riboside and NAD+. Ultraviolet detection at approximately 260 nm can be used for purity checks when concentrations are sufficient. Nuclear magnetic resonance spectroscopy provides structural confirmation and can distinguish anomeric forms.
Stability testing examines how temperature, humidity, light, and pH affect NMN over time. The compound is generally considered hygroscopic and may degrade faster in aqueous solution than in dry powder form. Phosphate esters can hydrolyze under strongly acidic or alkaline conditions, and elevated temperatures accelerate such reactions. For storage, sealed containers at low temperature with desiccant are typical laboratory practices. Stability-indicating methods should separate NMN from its degradation products, including nicotinamide and nicotinamide riboside, so that purity loss can be tracked accurately.
Quality control for NMN materials typically includes identity, assay, impurity, and residual solvent tests. Certificates of analysis may report HPLC purity, water content, heavy metals, and microbial limits depending on the intended use. Because commercial NMN is sold as a research chemical or ingredient rather than a standardized drug in many jurisdictions, specifications can vary between suppliers. Independent verification can involve comparing retention time, mass spectrum, and NMR data against a reference standard. Open questions remain about how best to standardize purity claims and biological potency across different production methods.
== Form and appearance == Heinz bodies appear as small round inclusions within the red cell body, though they are not visible when stained with Romanowsky dyes. They are visualized more clearly with supravital staining (e.g., with new methylene blue, crystal violet or bromocresol green).
2.4×1034 years for decay to a positron and a neutral pion (p → e+ + π0), 1.6×1034 years for decay to an antimuon and a neutral pion (p → μ+K0), 0.59×1034 years for decay to an muon antineutrino and a positive kaon (p → ν̄K+). Two Nobel prizes for neutrino physics were awarded to scientists based on work using experimental facilities originally designed to detect proton decay. In 2002, Masatoshi Koshiba was awarded "for pioneering contributions to astrophysics, in particular for the detection of cosmic neutrinos", by upgrading the KamiokaNDE experiment. (sharing half prize with Raymond Davis Jr. for the same motivations).T. Kajita of the Super-Kamiokane collaboration was awarded the 2015 Nobel Prize "for the discovery of neutrino oscillations, which shows that neutrinos have mass", jointly to Art McDonald of the SNO experiment.
A study found comparable absorption of transdermal estradiol patches (within ±25% of reference) for a number of skin sites including the abdomen, upper arm, upper thigh, lower back, and side. However, absorption was 15% lower for the upper thigh compared to the abdomen and the difference was significant. Another study found that transdermal estradiol patches had 20 to 25% higher bioavailability when applied to the buttocks than when applied to the abdomen. Studies of topical steroids have found that the scrotum is especially permeable among skin sites. Studies of transdermal testosterone cream, gel, and patches applied to the scrotum in men have observed 5- to 8-fold higher levels of testosterone than with application to conventional skin sites. In a study of topical application of hydrocortisone solution in men, skin permeability (defined as total radiolabeled urinary excretion) relative to the forearm (1.0) was 42.0 for the scrotum, 13.0 for the jaw angle, 6.0 for the forehead, 3.6 for the underarm, 3.5 for the scalp, 1.7 for the back, 0.8 for the palm of the hand, 0.4 for the ankle, and 0.1 for the sole of the foot. In accordance with findings with other topical steroids, a study in men with prostate cancer treated with transdermal estradiol patches applied to the scrotum observed about 5-fold higher estradiol levels relative to application to conventional skin sites such as the forearm. Penile skin may have similarly enhanced absorption characteristics relative to scrotal skin.
An overview of the history was published in 2012. In 1934, the Hungarian physician Paul György discovered a substance that was able to cure a skin disease in rats (dermatitis acrodynia). He named this substance vitamin B6, as numbering of the B vitamins was chronological, and pantothenic acid had been assigned vitamin B5 in 1931. In 1938, Richard Kuhn was awarded the Nobel Prize in Chemistry for his work on carotenoids and vitamins, specifically B2 and B6. Also in 1938, Samuel Lepkovsky isolated vitamin B6 from rice bran. A year later, Stanton A. Harris and Karl August Folkers determined the structure of pyridoxine and reported success in chemical synthesis, and then in 1942 Esmond Emerson Snell developed a microbiological growth assay that led to the characterization of pyridoxamine, the aminated product of pyridoxine, and pyridoxal, the formyl derivative of pyridoxine. Further studies showed that pyridoxal, pyridoxamine, and pyridoxine have largely equal activity in animals and owe their vitamin activity to the ability of the organism to convert them into the enzymatically active form pyridoxal-5-phosphate. Following a recommendation of IUPAC-IUB in 1973, vitamin B6 is the official name for all 2-methyl,3-hydroxy,5-hydroxymethylpyridine derivatives exhibiting the biological activity of pyridoxine. Because these related compounds have the same effect, the word "pyridoxine" should not be used as a synonym for vitamin B6.
Sources: en.wikipedia.org
Critical illness polyneuropathy (CIP) and critical illness myopathy (CIM) are overlapping syndromes of diffuse, symmetric, flaccid muscle weakness occurring in critically ill patients and involving all extremities and the diaphragm with relative sparing of the cranial nerves. CIP and CIM have similar symptoms and presentations and are often distinguished largely on the basis of specialized electrophysiologic testing or muscle and nerve biopsy. The causes of CIP and CIM are unknown, though they are thought to be a possible neurological manifestation of systemic inflammatory response syndrome. Corticosteroids and neuromuscular blocking agents, which are widely used in intensive care, may contribute to the development of CIP and CIM, as may elevations in blood sugar, which frequently occur in critically ill patients. CIP was first described by Charles F. Bolton in a series of five patients. Combined CIP and CIM was first described by Nicola Latronico in a series of 24 patients.
==== Altered oxygen sensing ==== Rare inherited mutations in three genes which all result in increased stability of hypoxia-inducible factors, leading to increased erythropoietin production, have been shown to cause secondary polycythemia:
=== Target incubation === Immediately prior to target introduction, the single stranded oligonucleotide library is often heated and cooled slowly to renature oligonucleotides into thermodynamically stable secondary and tertiary structures. Once prepared, the randomized library is incubated with immobilized target to allow oligonucleotide-target binding. There are several considerations for this target incubation step, including the target immobilization method and strategies for subsequent unbound oligonucleotide separation, incubation time and temperature, incubation buffer conditions, and target versus oligonucleotide concentrations. Examples of target immobilization methods include affinity chromatography columns, nitrocellulose binding assay filters, and paramagnetic beads. Recently, SELEX reactions have been developed where the target is whole cells, which are expanded near complete confluence and incubated with the oligonucleotide library on culture plates. Incubation buffer conditions are altered based on the intended target and desired function of the selected aptamer. For example, in the case of negatively charged small molecules and proteins, high salt buffers are used for charge screening to allow nucleotides to approach the target and increase the chance of a specific binding event.
Sources: en.wikipedia.org
Paul Halverson, director and state health officer for the Arkansas Department of Health, approved an emergency rule to ban the sale and distribution of phenazepam shortly after the Louisiana ban. Alabama made phenazepam a Schedule I substance on March 18, 2014.
In accordance, second-generation NSAAs like enzalutamide and apalutamide, which have 5- to 10-fold higher affinity for the AR than bicalutamide, have been found to be more effective than bicalutamide in the treatment of prostate cancer. However, in the TERRAIN and STRIVE trials, which compared bicalutamide and enzalutamide as a component of CAB and found that enzalutamide extended life by 3 to 4 times as much time as bicalutamide, the dosage of enzalutamide used (160 mg) was over 3 times that of the dosage of bicalutamide used (50 mg). As a result, it has been suggested that the 50 mg/day dosage of bicalutamide used in this study and in CAB in general may be suboptimal. This is in accordance with clinical findings that PSA decreases with CAB using bicalutamide plateau at a dosage of bicalutamide of 150 to 200 mg/day. In women, total testosterone levels are 20-fold and free testosterone levels 40-fold lower relative to men. In addition, whereas bicalutamide monotherapy can increase testosterone levels by up to 2-fold in men, the medication does not increase testosterone levels in women. For these reasons, much lower dosages of bicalutamide (e.g., 25 mg/day in the hirsutism studies) may be used in women with significant antiandrogenic effectiveness.
== History == Fenfluramine as a single drug was first introduced in the 1970s, but was not popular because it only temporarily reduced weight. A 1984 study found a weight loss of 7.5 kg on average in 24 weeks, as compared to 4.4 kg under placebo. It sold modestly until the 1990s, when it was combined with phentermine and heavily marketed.
Sources: en.wikipedia.org
Solid NMN is often stored frozen, desiccated, and protected from light. Aqueous solutions are less stable and generally require colder storage or fresh preparation.
Mass spectrometry and nuclear magnetic resonance spectroscopy are used for structural confirmation. Liquid chromatography with ultraviolet or mass spectrometric detection is common for purity and quantity.
No. Chemical purity indicates the material matches specification; it does not demonstrate absorption, biological activity, or clinical benefit. Those questions require controlled human studies.
NMN is commonly detected by HPLC-UV, LC-MS, or LC-MS/MS. These methods separate the compound from related substances and identify it by retention time and mass.